Spyre Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Spyre Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to advancing novel therapeutic solutions for individuals afflicted with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's pipeline emphasizes developing long-acting monoclonal antibodies through advanced antibody engineering and strategic combination approaches. Its leading investigational candidate, SPY001, is a human monoclonal immunoglobulin G1 antibody engineered to specifically target the α4β7 integrin pathway for treating IBD, encompassing ulcerative colitis and Crohn's disease. Recent positive interim Phase 1 data for SPY001 showcased a favorable safety profile and an extended half-life exceeding 90 days, potentially enabling quarterly or even semi-annual subcutaneous dosing, significantly less frequent than existing therapies. Spyre intends to commence a Phase 2 platform trial for SPY001 in ulcerative colitis in mid-2025. Furthermore, Spyre is progressing SPY002, comprising human monoclonal antibody candidates designed to interact with tumor necrosis factor-like ligand 1A (TL1A), which has also shown potential for quarterly dosing with a half-life over three times longer than first-generation alternatives. The company's portfolio also includes SPY003, an anti-IL-23 monoclonal antibody, with first-in-human dosing expected in early 2025 and the potential for quarterly or twice-yearly maintenance dosing. Early-stage studies also explore combination therapies, such as SPY120 (combining SPY001 and SPY002), SPY130 (combining anti-α4β7 and anti-IL-23), and SPY230 (combining anti-TL1A and anti-IL-23), which aim to enhance efficacy and convenience. The company is expanding its SPY002 program to include rheumatoid arthritis, with a Phase 2 trial anticipated to start in mid-2025. Originally incorporated in 2013, the company operated as Aeglea BioTherapeutics, Inc. before adopting the name Spyre Therapeutics, Inc. in November 2023. It maintains its operations in Waltham, Massachusetts. Spyre Therapeutics maintains a robust financial position, with cash and marketable securities anticipated to provide a runway into the second half of 2028.
Company News
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy?
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
California State Teachers Retirement System Buys 5,683,670 Shares of Spyre Therapeutics, Inc. $SYRE
11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?